Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$1.37 - $3.4 $739 - $1,836
540 Added 95.91%
1,103 $1,000
Q3 2023

Oct 30, 2023

BUY
$1.37 - $3.4 $739 - $1,836
540 Added 95.91%
1,103 $2,000
Q2 2023

May 21, 2024

SELL
$2.13 - $7.13 $38 - $128
-18 Reduced 3.1%
563 $1,000
Q2 2023

Jul 27, 2023

SELL
$2.13 - $7.13 $38 - $128
-18 Reduced 3.1%
563 $1,000
Q1 2023

May 21, 2024

BUY
$5.52 - $9.23 $805 - $1,347
146 Added 33.56%
581 $3,000
Q1 2023

Apr 27, 2023

BUY
$5.52 - $9.23 $805 - $1,347
146 Added 33.56%
581 $3,000
Q4 2022

May 21, 2024

BUY
$7.72 - $21.27 $3,358 - $9,252
435 New
435 $3,000
Q4 2022

Jan 31, 2023

BUY
$7.72 - $21.27 $463 - $1,276
60 Added 16.0%
435 $4,000
Q3 2022

Oct 21, 2022

BUY
$13.43 - $18.74 $5,036 - $7,027
375 New
375 $5,000

Others Institutions Holding ACET

About Adicet Bio, Inc.


  • Ticker ACET
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,030,800
  • Market Cap $36M
  • Description
  • Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
More about ACET
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.